Omeros: Yartemlea Can Own The Label And Still Split The Market [Seeking Alpha]
Omeros Corporation (OMER)
Last omeros corporation earnings: 3/2 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.omeros.com
Company Research
Source: Seeking Alpha
YARTEMLEA's market opportunity is constrained by a small, fragmented TA-TMA market, operational complexities, and likely payer pushback on aggressive pricing. Updated modeling assumes a 40% peak share and ~$250k net price, yielding a ~$300M NPV for YARTEMLEA with significant uncertainty in uptake and pricing. OMER's valuation is supported by the Novo Nordisk zaltenibart partnership, but no new clinical catalysts are imminent; current sub-$1B valuation feels appropriate, not cheap. SvetaZi/iStock via Getty Images Overview My last review of Omeros Corporation ( OMER ) was immediately following the FDA approval of YARTEMLEA (narsoplimab) for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The good news happened just about two months after a blockbuster licensing This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such po
Show less
Read more
Impact Snapshot
Event Time:
OMER
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OMER alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OMER alerts
High impacting Omeros Corporation news events
Weekly update
A roundup of the hottest topics
OMER
News
- Omeros Announces Successful Primate Study in OncotoX-AML™ Drug ProgramBusiness Wire
- Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.MarketBeat
- Omeros Announces First Commercial Sales of YARTEMLEA®Business Wire
- Thrombotic Microangiopathy Global Clinical Trials Market Review Report 2025 [Yahoo! Finance]Yahoo! Finance
- Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.MarketBeat
OMER
Earnings
- 11/13/25 - Beat
OMER
Sec Filings
- 2/20/26 - Form 4
- 1/30/26 - Form SCHEDULE
- 1/14/26 - Form 4
- OMER's page on the SEC website